ArticleMedical physics2026
CT radiomics for noninvasive prediction of histologic differentiation in gastric cancer.
Article in Medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe histological differentiation grade of gastric cancer critically influences treatment and prognosis. While CT radiomics shows promise for noninvasive prediction, its relationship with gene expression remains unclear. PURPOSE: This study aimed to develop a clinical-radiomics model for predicting tumor differentiation in gastric cancer patients and to explore the underlying mechanisms.
methodsWe retrospectively analyzed clinical data and CT images from 162 gastric cancer patients, who were randomly assigned to training and validation cohorts. The least absolute shrinkage and selection operator (LASSO) method was used to select features and construct the Rad-score. Subsequently, clinical-radiomics models were built and evaluated for their predictive efficacy and clinical incremental value. Furthermore, hub genes were screened, and their associated pathways were investigated using machine learning, bioinformatics analysis, and experimental validation.
resultsA clinical-radiomics model based on N stage, M stage and Rad-score was developed. The receiver operating characteristic (ROC) curves indicated that the model had preliminary evidence of predictive potential within this single-center cohort (training AUC = 0.872, validation AUC = 0.935). The calibration curves indicated a reasonable concordance between the observed values and the predicted outcomes in this retrospective sample. The decision curve analysis demonstrated a net benefit that requires further confirmation in external cohorts. The clinical impact curve (CIC) demonstrated the model's potential clinical applicability, which warrants validation in prospective settings. Sequencing data further revealed that the key gene IGHG1 was significantly associated with the Rad-score, with potential mechanisms involving the TGF-beta signaling pathway.
conclusionsThe clinical-radiomics model, incorporating N stage, M stage, and Rad-score, serves as a preliminary research tool for assessing tumor differentiation in gastric cancer patients within a single-center setting. External validation is required before any consideration of clinical generalization. Radiomics enables noninvasive evaluation of differentiation status while generating hypotheses regarding its underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.